针对IF1-ATP合成酶复合体的片调节癌症HeLa细胞中的透性过渡孔
Martina Grandi1, Simone Fabbian2, Giancarlo Solaini1
1Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy.
International journal of molecular sciences
|May 11, 2024
概括
线粒体蛋白IF1通过抑制亡促进癌症. 研究人员开发了针对IF1-OSCP相互作用的,通过破坏这种亲瘤性途径,显示出新的抗癌疗法的潜力.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 线粒体蛋白IF1在许多瘤中被上调.
- IF1通过与ATP合成酶相互作用并抑制亡,作为一种亲瘤性蛋白质.
- 正在研究IF1-Oligomycin敏感性授予蛋白 (OSCP) 相互作用的精确分子性质及其治疗潜力.
研究的目的:
- 研究IF1-OSCP相互作用作为新型抗癌治疗干预措施的潜在目标.
- 为了生成和描述设计用于从OSCP中取代IF1的线粒体向化物.
主要方法:
- 产生针对线粒体的.
- 免疫沉以确认IF1从ATP合成酶的移位.
- 核磁共振 (NMR) 光谱法用于识别与OSCP结合的.
- 用衍生物对HeLa细胞进行现场处理.
主要成果:
- 一种选择性成功地将IF1从ATP合成酶中取代.
- 核磁共振检测出一种与OSCP N终端区域有亲缘关系的,重叠在IF1结合部位.
- 在IF1-沉默的HeLa细胞中,酸治疗抑制了线粒体透性过渡,而不影响呼吸.
- 第三个可以抵消IF1.1的抗亡作用.
结论:
- IF1-OSCP的相互作用在抑制癌细胞的亡中起着至关重要的作用.
- 针对IF1-OSCP与特定的相互作用,可以破坏这种亲瘤性途径.
- 在开发新型抗癌疗法方面,OSCP是一个有前途的目标.
相关概念视频
Translocation of Proteins into the Mitochondria
3.1K
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
3.1K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
ATP Synthase: Mechanism
14.5K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
14.5K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
ATP Driven Pumps III: V-type Pumps
3.7K
V-type pumps are ATP-driven pumps found in the vacuolar membranes of plants, yeast, endosomal and lysosomal membranes of animal cells, plasma membranes of a few specialized eukaryotic cells, and some prokaryotes. They are also known as the V1Vo-ATPase, that couple ATP hydrolysis to transport protons against a concentration gradient.
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
3.7K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


